MaxCyte reports Q4 EPS (9c), consensus (8c)

Reports Q4 revenue $7.3M, consensus $9.16M. “Our 2025 revenues were impacted by headwinds from select SPL customers, including a 15% reduction in purchases and leases from our largest customer, which we expect to stabilize in the second half of 2026 and grow from that new base. Despite these near-term challenges, we made meaningful progress in 2025: reducing annual cash burn by more than $16 million, streamlining our cost structure, and advancing new product launches, all which we believe will strengthen MaxCyte’s (MXCT) position in the growing cell and gene therapy market for the long term,” said Maher Masoud, president and CEO of MaxCyte.